IDH1 Mutation Analysis; IDH2 Mutation Analysis
IDH1 or IDH2 mutations are detected in approximately 15-20% of acute myeloid leukemia (AML) and >70% grade II or III brain gliomas. Patients with AML and mutations are likely to have aggressive disease, while mutations in gliomas are associated with better prognosis. Long-term survival after aggressive tumor resection has been reported for patients with IDH1-positive astrocytomas
FFPE tissue: Paraffin block
Refrigerate, and use cold pack for transport, cold pack should not be in direct contact with specimen
Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Refer to Interpretive Results
IDH1 or IDH2 mutations are detected in approximately 15-20% of acute myeloid leukemia (AML) and >70% grade II or III brain gliomas. Patients with AML and mutations are likely to have aggressive disease, while mutations in gliomas are associated with better prognosis. Long-term survival after aggressive tumor resection has been reported for patients with IDH1-positive astrocytomas
7 to 8 days
00918891, 00918892
81120, 81121